mRNA Stock - Search News

Agrees to review Moderna flu vaccine

Moderna jumps above 20-day moving average on FDA flu vaccine review. Should you buy MRNA stock here?

Moderna (MRNA) stock closed higher on Wednesday after the FDA reversed its earlier refusal-to-file decision on the company’s mRNA-1010 seasonal influenza vaccine. As the regulatory agency agreed to review MRNA’s revised application,

Zacks Investment Research on MSN · 10h

Moderna stock jumps after FDA reverses course on flu shot

· 1d

FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars

· 21h

FDA reverses course on Moderna's flu vaccine

The FDA says it will now review a new m-r-n-a flu vaccine from Moderna.

· 1d

FDA reverses course and will review Moderna’s mRNA flu shot, company says

· 1d

FDA plans review of Moderna flu vaccine for older adults

· 1d

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

The FDA news is largely positive for MRNA stock as it positions the company’s influenza vaccine for the upcoming flu season.

· 1d

FDA reverses course, agrees to review Moderna's flu vaccine

· 1d

FDA Reverses Course and Will Now Review Moderna’s Flu Shot

How to Buy Moderna Stock (MRNA) in 2026

Moderna is a well-known biotech company from its pandemic success. Here's what investors should know about its growth story now.

Schaeffer's Investment Research

Moderna Stock Pops as FDA Application Moves Forward

Moderna (MRNA) stock is on the rise after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine application for review

Blockonomi

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.

10d

Moderna (MRNA) Laps the Stock Market: Here's Why

Moderna (MRNA) closed at $41.95 in the latest trading session, marking a +2.29% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. Meanwhile, the Dow experienced a rise of 0.

Forbes

What Is Going On With Moderna Stock?

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over the last 5 days, leading to a current market ...

6don MSN

4 stocks to watch on Friday: MRNA, TWLO, ANET, LLY

Stock index futures were little changed on Friday as traders awaited key retail inflation data due out ahead of the opening bell. Here are the four stocks to watch on the day: Moderna (MRNA) rose 0.2% in premarket trading after reporting better-than-expected Q4 2025 financials on Friday.